- Home
- CRT vs MIST Comparison
CRT vs MIST Comparison
Compare CRT & MIST Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | CRT | MIST |
|---|---|---|
| Founded | 1991 | 2003 |
| Country | United States | Canada |
| Employees | N/A | N/A |
| Industry | Oil & Gas Production | Biotechnology: Pharmaceutical Preparations |
| Sector | Energy | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 42.5M | 163.2M |
| IPO Year | 1992 | N/A |
Fundamental Metrics
Financial Performance| Metric | CRT | MIST |
|---|---|---|
| Price | $7.52 | $2.12 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 4 |
| Target Price | N/A | ★ $8.50 |
| AVG Volume (30 Days) | 22.3K | ★ 9.4M |
| Earning Date | 03-12-2026 | 11-12-2025 |
| Dividend Yield | ★ 10.10% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.74 | N/A |
| Revenue | ★ $5,621,913.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $9.90 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $7.07 | $0.63 |
| 52 Week High | $13.31 | $3.06 |
Technical Indicators
Market Signals| Indicator | CRT | MIST |
|---|---|---|
| Relative Strength Index (RSI) | 40.92 | 40.77 |
| Support Level | $7.34 | $2.00 |
| Resistance Level | $8.36 | $2.22 |
| Average True Range (ATR) | 0.30 | 0.32 |
| MACD | -0.12 | -0.09 |
| Stochastic Oscillator | 25.66 | 34.83 |
Price Performance
Historical ComparisonAbout CRT Cross Timbers Royalty Trust
Cross Timbers Royalty Trust is a United States-based trust. The net profits interests are derived from producing royalty, overriding royalty interests, and working interest properties. The underlying properties of the trust include producing properties in Texas, Oklahoma, and New Mexico.
About MIST Milestone Pharmaceuticals Inc.
Milestone Pharmaceuticals Inc is a biopharmaceutical company dedicated to developing and commercializing etripamil for the treatment of cardiovascular medicines. Etripamil is a calcium channel blocker developed as a rapid-onset nasal spray to be administered by the patient to treat episodes of paroxysmal supraventricular tachycardia, or PSVT. The company has an ongoing Phase 2 clinical trial for patients with atrial fibrillation experiencing a rapid ventricular rate (AFib-RVR).